NEVRO CORP. (NYSE:NVRO) Files An 8-K Results of Operations and Financial Condition

Item 2.02

On May 8, 2017, Nevro Corp. (Nevro or the Company) issued a press
release relating to its financial results for the three months
ended March 31, 2017. The full text of the press release is
furnished herewith as Exhibit 99.1.

The information in this Item 2.02 of this Form 8-K and the
Exhibit 99.1 attached hereto shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

About NEVRO CORP. (NYSE:NVRO)

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

NEVRO CORP. (NYSE:NVRO) Recent Trading Information

NEVRO CORP. (NYSE:NVRO) closed its last trading session down -4.47 at 86.30 with 427,370 shares trading hands.